Anti-Leukemic and Anti-GVHD Effects of Campath-1H in Acute Lymphoblastic Leukemia Relapsed after Stem-Cell Transplantation

Pier Paolo Piccaluga Institute of Haematology and Medical Oncology “L. and A. Seràgnoli”, S. Orsola-Malpighi Hospital, University of Bologna, ItalyCorrespondence[email protected]

Giovanni Martinelli Department of Haematology, S. Salvatore Hospital, Pesaro, Italy

Michele Malagola Institute of Haematology and Medical Oncology “L. and A. Seràgnoli”, S. Orsola-Malpighi Hospital, University of Bologna, Italy

Michela Rondoni Department of Haematology, S. Salvatore Hospital, Pesaro, Italy

Michele Bianchini Institute of Haematology and Medical Oncology “L. and A. Seràgnoli”, S. Orsola-Malpighi Hospital, University of Bologna, Italy

Ernesto Vigna Department of Haematology, S. Salvatore Hospital, Pesaro, Italy

Costanza Bosi Institute of Haematology and Medical Oncology “L. and A. Seràgnoli”, S. Orsola-Malpighi Hospital, University of Bologna, Italy

Stavroula Gaitani Department of Haematology, S. Salvatore Hospital, Pesaro, Italy

Giuseppe Visani Institute of Haematology and Medical Oncology “L. and A. Seràgnoli”, S. Orsola-Malpighi Hospital, University of Bologna, Italy

Michele Baccarani Department of Haematology, S. Salvatore Hospital, Pesaro, Italy

show all

Abstract

Despite aggressive approaches, including second transplant, donor lymphocyte infusion and several new agents, the prognosis of acute lymphoid leukemia (ALL) patients relapsing after stem-cell transplantation (SCT) remains poor. Monoclonal-antibodies (moAb) could provide a useful tool in this setting. In particular, anti-CD52 moAb is useful in lymphoid malignancies. We thus treated as compassionate with campath-1H 3 ALL patients relapsed after SCT. In 2 cases we observed a reduction of peripheral blood and/or bone marrow blasts. In 1 case a GVHD grade reduction was observed. Larger trials are required in order to define the role of campath-1H in ALL.

Keywords

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Anti-Leukemic and Anti-GVHD Effects of Campath-1H in Acute Lymphoblastic Leukemia Relapsed after Stem-Cell Transplantation

Information for

Open access

Opportunities

Help and information

Anti-Leukemic and Anti-GVHD Effects of Campath-1H in Acute Lymphoblastic Leukemia Relapsed after Stem-Cell Transplantation

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature